my account  log out
 

Coluracetam (MKC-231)

Create: 07/09/2019
Expired Date:12/31/2019
Category: Chemical
Message:Coluracetam is a nootropic drug of the racetam family. Coluracetam was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depression disorder (MDD), after being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from its Phase 2a clinical trials have suggested that it would be an ideal medication for co-morbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury. Coluracetam (MKC-231) is a synthetic Racetam drug purported to be a Nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structute) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam. Web: www.rawsgear.com Web: www.rawsgearpharma.com Email: gear@quality-steroid.com Skype: +8615711952876 Whatsapp +8615711952876
City:wuhan[US] 
Location:
 
Jul 09 2019Armodafinil184
Jul 09 2019Phenibut187
Jul 09 2019Sertraline Hydrochloride190
Jul 09 2019Carphedon188
Jul 09 2019Coluracetam (MKC-231)166
Jul 09 2019Oxiracetam155
Jul 09 2019Aniracetam166
Jul 09 2019Pramiracetam165
Jul 09 2019Piracetam166
Jul 09 2019Noopept CAS 157115-85-0164

return back

Copyright © toextrade Inc. All rights reserved. Contact us